Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published Date August 2008 Volume 2008:4(5) Pages 937—948

DOI http://dx.doi.org/10.2147/NDT.S3369

Published 11 August 2008

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Bone resorption in incompletely impacted mandibular third molars and acute pericoronitis

Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.

Clinical, Cosmetic and Investigational Dentistry 2009, 1:7-12

Published Date: 14 April 2009

Effects of selective serotonin reuptake inhibitors on motor neuron survival

Lily B Anderson, Phaedra B Anderson, Thea B Anderson, Amy Bishop, et al.

International Journal of General Medicine 2009, 2:109-115

Published Date: 28 May 2009

Pillow use: the behavior of cervical stiffness, headache and scapular/arm pain

Susan J Gordon, Karen A Grimmer-Somers, Patricia H Trott

Journal of Pain Research 2010, 3:137-145

Published Date: 11 August 2010

Multinational Internet-based survey of patient preference for newer oral or injectable Type 2 diabetes medication

Marco daCosta DiBonaventura, Jan-Samuel Wagner, Cynthia J Girman, et al

Patient Preference and Adherence 2010, 4:397-406

Published Date: 3 November 2010

Progesterone prevents development of neuropathic pain in a rat model: Timing and duration of treatment are critical

Henry JL, Dableh LJ

Journal of Pain Research 2011, 4:91-101

Published Date: 5 April 2011

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies

Tawara K, Oxford JT, Jorcyk C

Cancer Management and Research 2011, 3:177-189

Published Date: 18 May 2011

Comparison of two treatments for coxarthrosis: local hyperthermia versus radio electric asymmetrical brain stimulation

Castagna A, Rinaldi S, Fontani V, Mannu P, Lotti Margotti M

Clinical Interventions in Aging 2011, 6:201-206

Published Date: 25 July 2011

Functionalized carbon nanomaterials: exploring the interactions with Caco-2 cells for potential oral drug delivery

Coyuco JC, Liu Y, Tan BJ, Chiu GNC

International Journal of Nanomedicine 2011, 6:2253-2263

Published Date: 10 October 2011